SFG
KROS icon

SVB Financial Group’s Keros Therapeutics KROS Stock Holding History

SVB Financial Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,653
Closed -$223K – 30
2022
Q4 		$223K Buy
+4,653
New +$217K 0.61% 14

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SVB Financial Group's KROS Position: Q1 2023 in Review

SVB Financial Group sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 4,653 shares — an estimated $223K sold.

SVB Financial Group first reported a position in KROS in Q4 2022 and held it in 1 quarter. The position peaked at $223K in Q4 2022. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

  • SVB Financial Group reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
  • SVB Financial Group sold 4,653 Keros Therapeutics shares in Q1 2023, an estimated $223K.
  • SVB Financial Group first reported a position in Keros Therapeutics in Q4 2022 and held it in 1 quarter.
  • SVB Financial Group's Keros Therapeutics position peaked at $223K in Q4 2022.
  • 129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on SVB Financial Group's 13F filing for Q1 2023, filed 15 May 2023.